Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine.
Jordan E, Lawrence SJ, Meyer TPH, Schmidt D, Schultz S, Mueller J, Stroukova D, Koenen B, Gruenert R, Silbernagl G, Vidojkovic S, Chen LM, Weidenthaler H, Samy N, Chaplin P. Jordan E, et al. Among authors: weidenthaler h. J Infect Dis. 2021 Mar 29;223(6):1062-1072. doi: 10.1093/infdis/jiaa460. J Infect Dis. 2021. PMID: 32726422 Clinical Trial.
One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines.
Ilchmann H, Samy N, Reichhardt D, Schmidt D, Powell JD, Meyer TPH, Silbernagl G, Nichols R, Weidenthaler H, De Moerlooze L, Chen L, Chaplin P. Ilchmann H, et al. Among authors: weidenthaler h. J Infect Dis. 2023 May 12;227(10):1203-1213. doi: 10.1093/infdis/jiac455. J Infect Dis. 2023. PMID: 36408618 Free PMC article. Clinical Trial.
Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
Pittman PR, Hahn M, Lee HS, Koca C, Samy N, Schmidt D, Hornung J, Weidenthaler H, Heery CR, Meyer TPH, Silbernagl G, Maclennan J, Chaplin P. Pittman PR, et al. Among authors: weidenthaler h. N Engl J Med. 2019 Nov 14;381(20):1897-1908. doi: 10.1056/NEJMoa1817307. N Engl J Med. 2019. PMID: 31722150 Clinical Trial.
A Modified Vaccine against Smallpox. Reply.
Pittman PR, Weidenthaler H, Chaplin P. Pittman PR, et al. Among authors: weidenthaler h. N Engl J Med. 2020 Mar 26;382(13):1285-1286. doi: 10.1056/NEJMc2001156. N Engl J Med. 2020. PMID: 32212534 No abstract available.
The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform.
Volkmann A, Williamson AL, Weidenthaler H, Meyer TPH, Robertson JS, Excler JL, Condit RC, Evans E, Smith ER, Kim D, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group V3SWG. Volkmann A, et al. Among authors: weidenthaler h. Vaccine. 2021 May 21;39(22):3067-3080. doi: 10.1016/j.vaccine.2020.08.050. Epub 2020 Oct 17. Vaccine. 2021. PMID: 33077299 Free PMC article. Review.
Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.
Overton ET, Lawrence SJ, Wagner E, Nopora K, Rösch S, Young P, Schmidt D, Kreusel C, De Carli S, Meyer TP, Weidenthaler H, Samy N, Chaplin P. Overton ET, et al. Among authors: weidenthaler h. PLoS One. 2018 Apr 13;13(4):e0195897. doi: 10.1371/journal.pone.0195897. eCollection 2018. PLoS One. 2018. PMID: 29652929 Free PMC article. Clinical Trial.
12 results